Background: Most studies of post-transplant CMV infection have focused on either
| INTRODUC TI ON
Although there is extensive literature on CMV and CMV prevention in transplantation, [1] [2] [3] [4] [5] most studies have focused on either solid organ transplantation or HCT alone, and have rarely compared these 2 groups in terms of CMV incidence, risk factors, virologic features, and outcomes. The Organ Transplant Infection Prevention (OTIP) study is a 6-center cohort study involving lung transplant and HCT recipients with parallel data collection methodologies. Although originally established for the purpose of investigating the epidemiology and environmental risk factors for post-transplant fungal infections, the OTIP study design has provided a unique opportunity for comparing and contrasting various other infections in these 2
groups. 6 The current study focuses specifically on CMV infections in the OTIP cohort.
| ME THODS

| General
During Surveillance System criteria. 7 A uniform case report form and electronic data entry form developed by the Centers for Disease Control and Prevention (CDC) was used by all centers, and information was forwarded to a central data repository at CDC.
| Definitions
Definitions of tissue-invasive CMV disease (end-organ disease) and CMV viremia followed the standard definitions that were in use at the time of the study. 8 Although subsequently updated definitions have been published, 9 which should now replace the older definitions for clinical trials, the newer definitions were not yet published at the time this study was conducted. Therefore, "tissue-invasive CMV" indicated positive histopathology or a positive CMV immunostain on a tissue biopsy (except for CMV retinitis, which was diagnosed by ophthalmologic examination). "CMV viremia" was defined as any detection of CMV in blood by CMV quantitative polymerase chain reaction (CMV PCR) or pp65 antigenemia testing. For purposes of this study, data were not collected on the intermediate category of "CMV syndrome" which has been defined for solid organ transplant, but not HCT recipients, 8, 9 and in the current study, such patients were categorized as having CMV viremia rather than tissue-invasive disease, even if symptomatic. A CMV episode was considered resolved if the CMV PCR or antigenemia test was negative (undetectable) twice, on assays obtained at least 1 week apart, and a recurrence was defined as any CMV detection that occurred after at least 2 negative (undetectable) PCR or antigenemia test results had been obtained.
| CMV detection assays
CMV viral load monitoring was performed per each center's protocol. Most centers used CMV quantitative PCR assays during this time period, which was before the advent of the United States Food and Drug Administration (FDA)-approved PCR assay in IU/mL; therefore, CMV PCR assays were center-specific with results expressed as DNA copies/mL. A study core laboratory was not utilized in this study;
therefore, CMV PCR measurements were not standardized among centers. 10 One center used only pp65 antigenemia assays, and 2 centers used both pp65 antigenemia assays and CMV PCR assays.
Shell vial cultures for CMV were performed on bronchoalveolar lavage fluid per center protocol. Duration of CMV prophylaxis and use of preemptive strategies are described in the Results section below.
| Statistics and data analysis
Data collected by the 6 OTIP centers were transmitted to CDC via an electronic case report form. Data were collected in real time and forwarded at least monthly. Final data cleaning and statistical analysis were performed at the CDC. Chi-square and Fisher's exact tests, as appropriate, were used to compare categorical variables, and t tests and Wilcoxon rank-sum tests were used to compare continuous variables. In all analyses, the level of significance was set at α = .05. All analyses were done using SAS software (version 9.3, SAS Institute, Inc., Cary, NC).
| RE SULTS
| Patients and pre-transplant characteristics
Demographics and pre-transplant characteristics of the study patients are summarized in Tables 1 and 2 Tables 1 and 2 .
In the lung transplant cohort, 72/293 (24.6%) were in the highrisk CMV donor-seropositive, recipient-seronegative (D+/R−) group.
In the HCT cohort, 94/444 (21.2%) were in the high-risk CMV donorseronegative, recipient-seropositive group (D−/R+). In the lung transplant group, none of the characteristics listed in TA B L E 1 Selected demographics, pre-transplant, and transplant features of lung transplant recipients with and without CMV infection of those who had IgG's checked had very low levels (< 350 mg/dL).
| Overall incidence of CMV infection and risk factors for CMV
There was no association between CMV and IgG levels in lung recipients overall, but those with an IgG level of < 350 mg/dL had a higher incidence of CMV infection (P = .0424). Total IgG levels were checked in 300/444 (67.6%) of HCT recipients, and there was no association between IgG levels and CMV risk, despite 35.7% of those who had IgG checked having a low nadir IgG level (< 350 mg/dL).
| Donor and recipient serostatus and CMV risk
In the lung transplant group, the highest risk for developing CMV In contrast, HCT recipients in general did not receive prophylaxis against CMV, but instead were managed with a strategy of serial ATGAM, anti-thymocyte globulin; BMT, bone marrow transplant; GVHD, graft-vs-host disease; IgG, immunoglobulin G; PBSCT, peripheral blood stem cell transplant. a Checked in 67.6% of patients per clinician choice. Percentages refer to % of patients in whom IgG levels were checked.
*P values for all other conditioning regimen agents were not significant. **P values for all other GVHD prophylaxis agents were not significant. Fungal infections occurred in 24 lung transplant recipients (8.2%) and 48 HCT recipients (10.8%), with no significant differences in fungal infection incidence between the groups who did and did not develop CMV infection.
Antiviral agents other than ganciclovir and acyclovir derivatives were administered to relatively few lung recipients (6 foscarnet, 2 cidofovir, all of whom were in the group that developed CMV infection) and relatively more HCT recipients (40 foscarnet, 29 cidofovir).
The specific reasons for choice of antiviral agent were not recorded in this dataset. Among HCT recipients, 8 foscarnet and 11 cidofovir recipients were in the group that never developed CMV viremia, so these antiviral agents may have been administered for treatment of other viruses (eg, HSV, VZV, HHV-6, BKV, or adenovirus infection).
In addition, it is possible that some foscarnet use in the HCT group with CMV (32 patients) might have reflected clinicians' desire to avoid the hematologic toxicities of ganciclovir/valganciclovir in patients with pre-engraftment CMV or borderline neutropenia.
| Survival
Overall survival in this cohort at 6, 12, and 18 months was 89.4%, 82.9%, and 80.6% for lung transplant recipients, and 72.3%, 59.2%, and 54.3% for HCT recipients. There was no significant reduction in survival in either cohort between those who developed CMV infection and those who did not.
| D ISCUSS I ON
The results of this large multicenter cohort study highlight both the differences in host immunobiology and the effects of different antiviral prevention strategies between lung transplant and HCT recipients. This study demonstrates that CMV viremia remains common in both types of transplant recipients in the modern era, although tissue-invasive CMV disease has become uncommon with the use of current CMV prevention strategies. [1] [2] [3] [4] [5] Since HCT programs rely on preemptive monitoring rather than universal antiviral prophylaxis, 4, 5 it is not surprising that CMV viremia remains common in this group, but it also occurred in 28.3% of lung recipients despite prophylaxis.
Thus, it appears that the success of CMV prevention in both groups has not been in the complete suppression of viremia, but rather in the prevention of highly symptomatic CMV and end-organ CMV disease.
Recurrences of viremia were more common in HCT recipients the de novo acquisition of donor-transmitted CMV infection in a solid organ transplant recipient without antecedent CMV-specific immunity, whereas the latter reflects the reconstitution of a donor immune system without antecedent CMV-specific immunity in the context of a recipient at risk for reactivation of pre-existing latent CMV infection. This study also confirms that the risk of CMV viremia varies with the type of HCT, 11 for example higher risk in mismatchedunrelated HCT recipients, although these constituted only 4.5% of HCT recipients in this study. Cord transplant recipients constituted only a small fraction of patients in the current study, precluding meaningful comparisons.
Of note, although the number of patients with tissue-invasive CMV disease in this cohort was small, it is interesting to note that the sites of end-organ involvement showed a predominance of CMV pneumonitis in lung recipients, and gastrointestinal CMV in HCT recipients. Lung recipients have traditionally been noted to be at risk for CMV pneumonitis, given the propensity for CMV invasive disease to localize to the allograft. However, the finding that approx- 
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One of the original goals of this study was the comparison of infection outcomes between centers that do or do not use alemtuzumab induction in lung transplantation 13 ; we found that there was no significant difference in CMV infection in relation to alemtuzumab use in this cohort. Of the immunosuppressive agents administered, the only significant association was a lesser risk of CMV in HCT recipients who received methotrexate for GVHD prophylaxis. There was a trend toward increased CMV incidence in HCT recipients who received antilymphocyte therapy. Other immunosuppressive agents and acute rejection in lung recipients were not associated with differential CMV risk in this study. There may still be inherent increased risk associated with certain immunosuppressive regimens and with acute rejection, but this risk might have been compensated for by heightened awareness and interventions on the part of clinicians.
Hypogammaglobulinemia was common in both groups, but was not associated with CMV risk in this study, except in lung recipients in the lowest IgG group (<350 mg/dL). A previous study of hypogammaglobulinemia in lung transplantation had identified low IgG levels as associated with increased risk for tissue-invasive CMV disease, although not for CMV viremia in general. 14 On the other hand, any occurrence of GVHD in this study was associated with increased CMV risk in HCT recipients.
The effects of different CMV prevention strategies were evident in the time to CMV data. The standard of CMV prevention in lung transplantation has traditionally been prophylaxis using IV ganciclovir and more recently valganciclovir. The randomized trial of 3 vs 12 months valganciclovir prophylaxis by Palmer et al, 15 published when the current study was nearly completed, demonstrated the benefits of longer durations of prophylaxis in lung transplant recipients. Before that, there was already a trend toward longer prophylaxis in lung transplant programs, as seen in previous nonrandomized trials. 16, 17 The median prophylaxis duration of almost 6 months for lung transplant recipients in the current study was thus reflective of a shift in practice occurring around that time. Therefore, it is not surprising that the initial detection of CMV viremia occurred much later in lung transplant recipients ("late CMV" after completion of prophylaxis), 18 as compared with HCT recipients who received preemptive monitoring.
CMV infection and its treatment may predispose to fungal infections, either through cytopenias or by immunosuppressive effects of CMV itself, but we observed no significant difference in frequency of invasive fungal infections in patients who did and did not develop CMV in this study.
A comparison with incidence of CMV disease in other studies, and with historical incidence of CMV disease in previous eras, is illuminating. In the early years of lung transplantation, there was a high incidence of CMV pneumonitis and a high mortality, particularly in CMV primary infection. For example, in the pre-prophylaxis era, the incidence of CMV infection was 80%, and CMV disease occurred in 31% of all lung recipients. 19 In 1 study, prophylaxis using a delayed-ganciclovir regimen reduced these numbers to 48% and 10%, respectively. 19 The VAL038 study, 15 a randomized controlled trial which compared 3 vs 12 months of valganciclovir prophylaxis in lung transplant recipients, reported a 32% incidence of CMV disease in the short-course prophylaxis group. The numbers in our current study are closer to those of the long-course prophylaxis group in the VAL 038 study (which had a 4% incidence of CMV disease).
In of the above studies, tissue-invasive disease incidence was relatively low in the current era compared with the historical rates from the earlier years of BMT, in which as many as 43% developed CMV disease, frequently with CMV pneumonitis which was associated with a high mortality. 21 Somewhat surprisingly, we observed no association between CMV infection and reduction of overall survival in the current study. It is possible that other aspects in the modern era of CMV management, such as modulation of immunosuppression during and after viremia episodes, could theoretically have counterbalanced an adverse impact of CMV on survival. 
| LI M ITATI O N S
| CON CLUS IONS
Despite the limitations noted above, interesting comparisons have emerged between multicenter cohorts of lung transplant and HCT recipients in the modern era, with regards to CMV incidence, risk factors, clinical and virologic characteristics, and patient outcomes.
These likely reflect both the disparate nature of host responses to CMV, and also prevention strategies that are differentially applied to these groups because of the high risk of cytopenias in HCT recipients from prolonged use of valganciclovir and ganciclovir. Evidencedriven prophylaxis duration has become increasingly longer in lung transplant recipients, but preemptive monitoring and directed therapy remain the standard in HCT recipients. In both groups, the success of prevention strategies is reflected in an overall low incidence of tissue-invasive disease (despite a continued incidence of viremia) and the lack of a detrimental impact of CMV viremia on survival in both groups. Other findings include a significantly earlier onset of CMV viremia in HCT recipients, likely related to the use of preemptive therapy rather than prophylaxis, and also more CMV recurrences in the HCT group. The increased use of antivirals other than ganciclovir/valganciclovir in the HCT group with CMV may reflect the concerns of HCT clinicians regarding the risk of neutropenia from ganciclovir derivatives. Taken together, these results enable us to understand how far the field of CMV prevention has come, and also to provide historical background for assessments of the impact of new immunosuppressive and antiviral agents that may be introduced in the future. 
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